Introduction
Neurodegenerative cascades in Parkinson's disease (PD) involve protein aggregation and oxidative stress, although the triggers for these events are unknown. Changes in biometals have long been suspected to play a role in these cascades. Copper (Cu) is an important biometal in the brain, as exemplified by Menkes and Wilson's diseases; serious neurological disorders of Cu dyshomeostasis (de Bie et al., 2007; Schaefer and Gitlin, 1999) . A significant decrease in total tissue Cu in the degenerating substantia nigra (SN) in PD has been consistently reported over a number of decades (Ayton et al., 2012; Dexter et al., 1989; Loeffler et al., 1996; Popescu et al., 2009; Uitti et al., 1989) and recent evidence suggests that peripheral Cu metabolism is altered in PD (Larner et al., 2013) . The complexing of Cu with the PD-associated protein -synuclein increases aggregation and toxicity of this protein (Rose et al., 2011; Wang et al., 2010) , possibly via stimulation of free radical production (Meloni and Vasak, 2011) . On the other hand, Cu is also a critical cofactor in a range of cuproproteins, including the key protective cellular antioxidant superoxide dismutase 1 (SOD1) (McCord and Fridovich, 1969) . Studies in model systems demonstrate that Cu depletion is associated with reduced activity of SOD1 and a concomitant increase in free radical production, which can be normalized by Cu supplementation (Lombardo et al., 2003; Prohaska, 1983) . SOD1 activity is reduced in the plasma of PD patients (Torsdottir et al., 2006) and studies in animal models of PD suggest that overexpression of SOD1 increases neuronal survival (Battaglia et al., 2002; Botella et al., 2008; Tripanichkul et al., 2007) . These data suggest that a reduction in brain Cu in PD may reduce SOD1-mediated antioxidant defense and contribute to neurodegenerative cascades. In the following work, we investigated changes in neuronal Cu levels and transport pathways to determine if changes in Cu are associated with a reduced antioxidant capacity in regions of neurodegeneration in PD. Brain regions investigated included the SN and locus coeruleus (LC), the brain regions most vulnerable to neuronal loss and Lewy body pathology in PD, the anterior cingulate cortex (ACC) which is affected by Lewy body pathology later in the course of PD and has limited cell loss, and the occipital cortex (OCx), a non-degenerating region in PD (Braak et al., 2003; Harding et al., 2002) . Samples were collected within 48 hours of death, dissected using polytetrafluoroethylene-coated blades (ProSciTech, Queensland, Australia), and the fresh tissue samples frozen immediately in liquid nitrogen, then stored at -80°C prior to analysis. Fixed tissue samples were stored in formalin prior to cryo-microtome sectioning.
Due to limited tissue availability, not every brain region was used in every experiment.
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Measurement of neuronal and regional Cu levels
Total Cu levels within cells are the sum of different pools of Cu; free Cu and Cu bound to proteins. In the brain the majority of Cu is not free but is tightly regulated by being bound to a range of molecules, including Cu transport proteins and other molecules, such as neuromelanin (Bohic et al., 2008) , an intracellular pigment found in vulnerable regions of the PD brain (Hirsch et al., 1988) . Total Cu levels were quantified within single neurons as well as regions in thin sections (20 µm) cut from fixed or frozen tissue samples using synchrotron radiation X-ray fluorescence microscopy (SRXFM) and particle induced X-ray emission (PIXE) microscopy. Experiments were conducted using the microprobes endstation at ID22
beamline of the European Synchrotron Radiation Facility and at the Diamond Light Source I18 beamline, as previously described (Antharam et al., 2012; Bohic et al., 2008 
Primary antibodies used for detection of Cu transport proteins using Western blotting and immunohistochemistry
Primary antibodies used are detailed in Supplementary Table 4 . Specificity of each antibody was confirmed by including no primary antibodies and, for Atox1, by preadsorption of the Atox1 antibody with the antigen against which the primary antibody was raised (the antigen inserm-00968923, version 1 -1 Apr 2014 8 was not available for the other antibodies used). The ATPase antibodies used in this study have been well characterized in previous reports, and their specificity confirmed (Cater et al., 2007; Ke et al., 2006 
SDS-PAGE and Western blot analysis of Cu transport proteins
The following protein amounts were loaded onto 4-12% Bis-Tris Criterion pre-cast gels ( (1:1500), SOD1 (1:10,000), and TH (1:5000) overnight at 4 °C. Following incubation with horseradish peroxidase-conjugated mouse anti-goat IgG (1:10,000), goat anti-mouse IgG
(1:2,000), donkey anti-sheep/goat IgG (1:2,000), or donkey anti-rabbit IgG (1:5000), protein inserm-00968923, version 1 -1 Apr 2014 signals were obtained using an ECL Western blotting detection system (Bio-Rad) as per the manufacturer's instructions, and developed using the Chemi-Doc XRS (Bio-Rad). Signal intensities were quantified by densitometry using Quantity One® software (Bio-Rad) and normalized to -actin (1:10,000) levels. TH levels in the SN were quantified by Western blot to provide an indication of dopaminergic cell loss. As expected, TH levels in the PD SN were significantly reduced by 60% (p=0.013). Levels of the Cu transporters Ctr1
(subsequently referred to as TH-associated Ctr1 levels), Atox1, ATP7A, and ATP7B were calculated relative to TH levels in the SN.
Cu transport protein immunohistochemistry
Formalin fixed slide-mounted paraffin-embedded sections (7µm) were antigen retrieved by either incubation with Tris-EDTA buffer (0.01M Tris, 1 mM EDTA, pH 9.0) at 95 °C for 20 mins (Ctr1), or by microwave irradiation in citrate buffer (pH 6.0) for 15 mins (ATP7A and ATP7B). Non-specific peroxidases were blocked with 1% H 2 O 2 (Fronine Laboratory Supplies) in 50% ethanol for 30 mins at room temperature. Non-specific antigen sites were blocked with a mixture of 1% bovine serum albumin (BSA; Sigma) and 5% normal horse serum (NHS; Australis) (Ctr1), Animal Free Blocker™ (Vector Laboratories) (ATP7A), or 3% BSA (Sigma) (ATP7B), for 20 mins at room temperature. Primary antibodies for immunohistochemistry were used at the following dilutions: Ctr1 (1:100), ATP7A (1:300), ATP7B (1:1,000). Primary antibodies for Ctr1, ATP7A and ATP7B were detected using biotinylated IgG antibodies (Vector Laboratories) (1:200), followed by Vector Elite Kit tertiary antibody complex (Vector Laboratories) (1:100), and visualized using 3'3'-diaminobenzidine (DAB; Sigma) with a cresyl violet counterstain (Sigma). Images were taken using a Zeiss AxioCam HRc microscope. 
SOD1 Activity Assay
SOD activity was determined using SOD determination kit (Sigma, Cat. #19160) according to the manufacturer's instructions. Total SOD activity was measured in supernatants, and SOD2 activity was measured by the addition of 5 mM potassium cyanide (Sigma). SOD1 activity (units/μg protein) was measured as the difference between total SOD, and SOD2, activity.
The specific activity of SOD1 was determined by normalizing SOD1 activity (units/μg inserm-00968923, version 1 -1 Apr 2014 11 protein) to SOD1 protein levels. A single PD case was excluded from analysis due to a medication history of selegiline, demonstrated to increase midbrain SOD1 activity (Takahata et al., 2006) .
Statistical Analyses
Statistical analyses were performed using PASW v18 (SPSS inc.). Univariate analysis of variance followed by Bonferroni's t-test was used to test for differences between groups.
Linear regression was used to test for relationships between variables. A p-value of less than 0.05 was accepted as the level of significance.
Results

Decreased Cu precedes regional cell loss in PD
Quantitative analysis of fixed sections by SRXFM (Fig 1A-C) revealed a decrease in NMassociated Cu in the SN from PD and ILBD cases with respect to both age-matched controls (45% decrease in PD, p<0.0001 and 48% decrease in ILBD, p=0.0003) and AD cases (31% decrease in PD, p=0.003 and 34.5% decrease in ILBD, p=0.007) (Fig 1A) . Our finding of decreased NM-associated Cu levels in the PD SN was confirmed in fresh frozen tissue sections (65%, p<0.0001; Fig 2) . A representative set of selected SRXFM elemental images from typical NM-containing neurons is shown in Fig 2. SRXFM imaging of single pigmented neurons demonstrated that Cu was colocalized with NM and that there was no change in the spatial distribution of Cu between control and PD cases. Similarly, analysis of NM from LC neurons showed a 55% decrease in Cu content in PD compared with controls (p=0.001; Fig   1B) while no differences were seen in the grey matter of the OCx (Fig 1C) . This data confirms a specific reduction in Cu within remaining NM-pigmented neurons in PD and inserm-00968923, version 1 -1 Apr 2014 12 shows that this deficit occurs in cases with ILBD and limited cell loss, suggesting an early deficit that precedes cell death and clinical symptoms.
Complementary to SRXFM, we quantified intraneuronal Cu levels in separate tissue sections using micro-PIXE to assess Cu content in randomly sampled regions (683 mm x 683 mm) of the SN, LC, and OCx (Fig 1D-F) . Alignment of the carbon map and optical microscopic view allowed independent quantification of melanized and non-melanized tissue within each region. Elemental concentrations obtained using micro-PIXE were within the range of those obtained using SRXFM. Micro-PIXE analysis of NM-containing neurons confirmed a decrease in Cu-associated NM in PD (54%, p=0.0012) and ILBD (60%, p=0.004) compared with controls ( Fig 1D) . Importantly, the Cu decrease was also observed in NM from neurons of the LC (Fig 1E) but not in the OCx (Fig 1F) .
Quantification of iron (Fe) and zinc (Zn) levels by PIXE revealed a 49% increase in Fe Table 5 ). These findings were confirmed by SRXFM on an adjacent set of sections (26% increase in Fe, p< 0.05, Supplementary Table 6 ). In contrast, Fe levels were not altered in fixed tissue within multiple individual pigmented neurons, suggesting that chemical fixation masks changes in Fe in PD. No other changes were found for NM-associated elements investigated across the disease groups in either the SN or LC.
Reduced Ctr1 is an early change in regions of cell loss in PD
TH-associated Ctr1 was significantly reduced in the SN of the PD brain (50% reduction in Ctr1, p=0.017, Fig 3A) and was significantly correlated with TH-associated Cu levels (p=0.036; Fig 3B) and disease duration (p=0.008; Fig 3C) . We have previously described in the normal SN (Davies et al., 2013) robust Ctr1 staining localized with NM ( Fig 4A) . In the inserm-00968923, version 1 -1 Apr 2014
13 PD SN however, consistent with our Western blot data, NM-associated Ctr1 immunoreactivity was markedly reduced (Fig 4B) . Interestingly, this was restricted to SN dopaminergic neurons, as robust Ctr1 NM staining was observed in pigmented neurons in the nearby ventral tegmental area (VTA) and retrorubral field (Fig 4B, inset) . NM-associated Ctr1 immunoreactivity in the SN of AD cases was equivalent to that in control cases (Fig 4C) , in contrast, a marked reduction in NM-associated Ctr1 immunoreactivity was observed in the majority of SN neurons in cases of ILBD (Fig 4D) .
NM-associated Ctr1 staining in the control LC was more variable compared to the consistently robust staining observed in the control SN. However, while neurons strongly expressing Ctr1 were frequently observed in control ( Fig 4E) and AD cases (Fig 4G) , strong
Ctr1 immunoreactivity was rarely observed in the PD (Fig 4F) and ILBD LC (Fig 4H) .
We have previously described strong cytoplasmic expression of Ctr1 in neuronal cell bodies in the normal ACC (Davies et al., 2013) (Fig 5A) . Interestingly, in contrast to the PD SN and LC, strong cytoplasmic expression of Ctr1 was preserved in the ACC in PD (Fig 5B) , consistent with our Western blot data in this brain region (Fig 5C) . Immunoreactivity for ATP7A, ATP7B, and Atox1 in SN and ACC did not differ between PD and control cases.
Increased SOD1 levels relates to reduced Cu levels in regions of cell loss in PD
SOD1 levels and specific activity were not associated with age, PM delay, or tissue pH.
Consistent with our previous findings (Davies et al., 2013) , in the control brain Cu levels were significantly higher in the SN compared with those in the OCx and ACC (p=0.001, p≤0.001, respectively). Confirming the decrease in SN Cu at the neuronal level, total tissue Cu was reduced by 48% in the PD SN compared with control (p=0.032). Regional protein levels of SOD1 in the control SN, OCx, and ACC did not vary significantly, and were not correlated with Cu levels; in contrast in the PD SN there was significantly more SOD1 compared with inserm-00968923, version 1 -1 Apr 2014 14 the OCx and ACC (p=0.002, p=0.007, respectively; Fig 6A and B) and SOD1 levels were correlated with Cu levels (p=0.004; Fig 6C) .
Initial enhancement of SOD1 antioxidant activity in regions affected by late PD pathology
Specific activity of SOD1 did not vary between the regions studied in the control brains (p=1.000; Fig 7) , but in contrast, in the PD brains SOD1 specific activity was significantly greater in the ACC compared with the SN (p=0.032; Fig 7) , and there was a trend for increased SOD1 specific activity in the parkinsonian ACC compared with the control ACC (p=0.076; Fig 7) .
Discussion
The current data demonstrate that Cu, and the expression of the Cu transport protein Ctr1, are decreased within the intraneuronal environment of surviving dopaminergic neurons of the SN and LC in ILBD and PD (Fig 1, 2, 3 , and 4). As ILBD is suggested to represent preclinical PD (Dickson et al., 2009 ) and these cases had not taken anti-parkinsonian medications, this suggests these changes occur early in the disease process and are independent of treatment. As
Cu and Ctr1 levels were not altered in the degenerating LC in AD, it is unlikely that the reduction in Cu and Ctr1 observed in these regions in PD results simply from neurodegeneration per se. Further, as Cu and Ctr1 levels were unchanged in regions that do not degenerate in PD, it appears that this early decrease is specific to regions vulnerable to neuronal cell loss in this disorder.
Our data in the PD brain show an association between decreasing Ctr1 and Cu levels selectively in regions degenerating in PD (Fig 4) , with the decrease in Ctr1 in PD enhanced in patients with longer disease durations and greater cell loss (Fig 3) . Data from animal models inserm-00968923, version 1 -1 Apr 2014
show that a decrease in Ctr1 leads to significant neuronal dysfunction and death. Deletion of Ctr1 is embryonic lethal and epithelial cell-specific Ctr1 knockout mice display neonatal defects and severe growth and viability abnormalities (Nose et al., 2006) . In addition, organisms lacking Ctr1 are deficient in oxidative stress protection (Dancis et al., 1994; De Freitas et al., 2000; Knight et al., 1996) . While our data demonstrate a change in Ctr1 in the parkinsonian brain, the regulation of intracellular Cu is complex and other yet to be characterized Cu transport pathways may also be altered in PD. It has recently been shown, for example, that down-regulation of Ctr1 in a murine model of Wilson's disease is linked to the appearance of a redundant mechanism of Cu transport, the 2 kDa Small Copper Carrier, SCC (Gray et al., 2012) . A second Ctr protein, structurally related to Ctr1, has also been identified in mammals, designated Copper transporter 2 (Ctr2). This protein has not been identified in human tissue but is thought to play a role in low affinity Cu import (Bertinato et al., 2008) and in intracellular Cu mobilization (Rees and Thiele, 2007) .
To determine the functional consequences of reduced intraneuronal Cu, we assessed a key antioxidant cuproprotein in the brain, SOD1, and identified an associated increase in levels of SOD1 protein in the degenerating PD SN (Fig 6A and B) . The relationship we observed between Cu and SOD1 levels is consistent with the hypothesis that cellular Cu levels regulate SOD1 expression (Brown et al., 2004; Henchcliffe and Beal, 2008) . Despite this increase in SOD1 protein levels, specific activity of SOD1 was unchanged in the PD SN (Fig 7) . In contrast, in the ACC, where Cu and Ctr1 levels are normal SOD1 specific activity was increased above that in the SN of the same brains (Fig 7) and there was a trend for SOD1 specific activity to be higher in the parkinsonian, compared with the control ACC (Fig 7) . The Genetic alterations causing dysfunctional Cu transport proteins and reduced brain Cu levels result in severe neurodegeneration, as observed in Menkes disease (Kaler, 2011; Strausak et al., 2001) . The current understanding of neuronal death in PD supports a role for -synuclein and oxidative stress in these degenerative pathways. We have previously shown that the earliest deposition of -synuclein in the parkinsonian SN occurs on NM (Halliday et al., 2005) and both regional and NM-associated Cu levels are significantly higher in the normal SN and LC compared with other brain regions (Bohic et al., 2008; Davies et al., 2013) . High Cu levels promote the formation of oligomeric (toxic) forms of α-synuclein Our data demonstrate decreased cellular copper levels and disrupted copper pathways in vulnerable brain regions in PD, as well regional changes in SOD1 specific activity that reflect the pattern of neurodegeneration in PD. We also show that neuronal SOD1 protein levels are increased in association with a decrease in Ctr1 and Cu levels prior to cell loss in regions most vulnerable to PD-associated neurodegeneration. These changes are enhanced with increasing disease duration. The reduced activity of copper-dependent SOD1 shown here, and that of ceruloplasmin (Ayton et al., 2012) , suggests that a reduction in cellular Cu compromises the inserm-00968923, version 1 -1 Apr 2014 ability of these neurons to defend themselves against oxidative stress, consistent with the severity of cell loss observed in these vulnerable regions in the PD brain.
Figure legends were determined by Univariate analysis of variance followed by Bonferroni-corrected posthoc t-tests. Normal SN, n=8; ACC, n=8; and OCx, n=8. PD SN, n=6; ACC, n=7; and OCx, n=6.
SOD1 specific activity was determined by normalizing SOD1 activity (units/μg protein) to SOD1 protein levels. 
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